Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 million) Series D financing.
The investors who supported the round include Andera Partners, Avidity Partners, EQT Life Sciences, Invus, IP Group plc, Janus Henderson Investors, M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures, Piper Heartland, RA Capital Management, Sofinnova Partners, Schroders Capital, and SV Health Investors.
“This Series D accelerates our potential path to registration for both alnodesertib and ART6043, broadening development for the next generation of DNA damage response (DDR) therapeutics to indications among the highest of unmet need across pancreatic, colorectal, and breast cancers, where median survival is often measured in months,” said Mike Andriole, Chief Executive Officer of Artios.
In 2025, several European oncology-focused or adjacent BioTech startups secured notable funding rounds alongside Artios Pharma’s €99 million Series D.
Germany’s Tubulis raised €308 million to advance its antibody-drug conjugate platform, while France’s Adcytherix secured €105 million to progress its novel ADC pipeline. The UK also saw activity through T-Therapeutics, which extended its Series A to approximately €78.2 million for next-generation TCR-based therapies, and CHARM Therapeutics, which raised €68.5 million to develop treatments for resistant cancers. Switzerland’s NUCLIDIUM closed an €84 million Series B for its radiopharmaceutical platform, and France’s Exeliom Biosciences raised €2.85 million to advance immuno-oncology development.
Together, these financings represent roughly €646.6 million of capital flowing into European oncology and adjacent BioTech fields in 2025.
Artios’ €99 million raise represents a significant addition to this sector and places it in the upper echelon of funding rounds raised this year.
Nikola Trbovic, Managing Partner, SV Health Investors, added, “We are thrilled to have supported Artios’ evolution, from an early-stage DDR pioneer when we founded the company to the established company it has become, distinguished by a promising and differentiated pipeline. We look forward to continuing to do so as it deploys the Series D proceeds to drive late-stage development of alnodesertib as well as its pipeline.”
Founded in 2016, Artios is innovating next-generation approaches in the (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers.
The company’s clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Polθ) inhibitor ART6043, as well as its pre-clinical programs, including DDRi-ADCs, are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cell’s remaining survival mechanisms.
The Series D proceeds will expand the clinical evaluation of Artios’ lead program, alnodesertib, to enroll additional ATM-negative patients in each of second-line pancreatic cancer and third-line colorectal cancer, for which the programme was recently granted U.S. FDA Fast Track Designation.
At the AACR meeting in April 2025, Artios reported that alnodesertib, in combination with low-dose irinotecan, demonstrated a 50% confirmed overall response rate in patients with ATM-negative solid tumors at the recommended Phase 2 dose in the STELLA Phase 1/2a trial.
There are currently no approved therapies specifically for patients whose tumors harbor ATM-deficiency, a population where alnodesertib has demonstrated durable responses across eight different solid tumors.
The proceeds from the financing will also be used to initiate a Phase 2 randomised clinical trial for Artios’ second potential first-in-class candidate, ART6043, in patients with BRCA-mutant HER2-negative breast cancer who are eligible to receive a PARP inhibitor. The DNA polymerase Theta (Polθ) inhibitor, ART6043, demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals in data from a Phase 1/2a study presented at the ESMO Congress in September 2025.
The company is also advancing a first-in-class and highly differentiated DDR inhibitor-Antibody Drug Conjugate (DDRi-ADC) program and expects to name a lead candidate in Q1 2026.
Jake Simson, Partner, RA Capital Management, commented, “We are excited to co-lead this financing round to advance the next generation of DNA damage response therapeutics. Artios’ differentiated clinical programmes, alnodesertib and ART6043, together have the potential to meaningfully expand the impact of DDR-targeted therapies.
“The rate and durability of responses observed to date for alnodesertib across a range of solid tumors and the early clinical results with ART6043 underscore the strength of Artios’ approach and ability to deliver novel, potentially first-in-class treatments for patients while building significant long-term value.”
Read the orginal article: https://www.eu-startups.com/2025/11/e99-million-series-d-fuels-artios-expansion-of-precision-cancer-treatment-pipeline/
